LY3154207

positive allosteric modulator of the human Dopamine D1 receptor

Also Known As:

2-(2,6-Dichlorophenyl)-1-((1 S,3 R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one; Mevidalen

Networked: 7 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - LY3154207: 7

Experts

1.	Svensson, Kjell A: 4 articles (10/2022 - 01/2022)
2.	Pugh, Melissa: 3 articles (01/2022 - 01/2022)
3.	Biglan, Kevin M: 2 articles (03/2022 - 01/2022)
4.	Kielbasa, William: 2 articles (03/2022 - 01/2022)
5.	Ardayfio, Paul: 2 articles (01/2022 - 01/2022)
6.	Biglan, Kevin: 2 articles (01/2022 - 01/2022)
7.	Munsie, Leanne: 2 articles (01/2022 - 01/2022)
8.	Beck, James: 1 article (10/2022)
9.	Chen, Qi: 1 article (10/2022)
10.	Coates, David A: 1 article (10/2022)

Related Diseases

1.	Lewy Body Disease (Lewy Body Dementia) 01/01/2022 - "Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial." 01/01/2023 - "PRESENCE was a phase 2 clinical trial assessing the efficacy of mevidalen, a D1 receptor positive allosteric modulator, for symptomatic treatment of Lewy body dementia (LBD). " 01/01/2022 - "To assess the safety and efficacy of mevidalen for treatment of cognition in patients with Lewy body dementia (LBD). " 01/01/2022 - "PRESENCE was a Phase 2 trial assessing mevidalen for symptomatic treatment of Lewy body dementia (LBD). " 01/01/2022 - "These data support examining mevidalen for symptomatic treatment of patients with Parkinson disease and Lewy body dementia."
2.	Cognitive Dysfunction 10/01/2023 - "Accumulating preclinical and clinical evidence shows that several agents may provide beneficial effects on patients with PD and cognitive impairment, including ceftriaxone, ambroxol, intranasal insulin, nilotinib, atomoxetine, mevidalen, blarcamesine, prasinezumab, SYN120, ENT-01, NYX-458, GRF6021, fosgonimeton, INT-777, Neuropeptide S, silibinin, osmotin, cordycepin, huperzine A, fibroblast growth factor 21, Poloxamer 188, ginsenoside Rb1, thioredoxin-1, tangeretin, istradefylline and Eugenia uniflora. "
3.	Sleep Deprivation 03/01/2022 - "Mevidalen promoted wakefulness in mice after prior sleep deprivation and delayed sleep onset by 5.5- and 15.2-fold compared with vehicle-treated animals, after the 20 and 60 mg/kg PO doses, respectively, when compared with vehicle-treated animals. "
4.	Parkinson Disease (Parkinson's Disease) 01/01/2022 - "The safety, tolerability, motor effects, and pharmacokinetics of mevidalen were studied in patients with Parkinson disease. " 01/01/2022 - "These data support examining mevidalen for symptomatic treatment of patients with Parkinson disease and Lewy body dementia." 01/01/2022 - "In the Movement Disorder Society-United Parkinson's Disease Rating Scale, all patients taking mevidalen showed a better motor examination sub-score on day 6 compared to only some patients in the placebo group. " 01/01/2022 - "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease."
5.	Movement Disorders (Movement Disorder) 01/01/2022 - "In the Movement Disorder Society-United Parkinson's Disease Rating Scale, all patients taking mevidalen showed a better motor examination sub-score on day 6 compared to only some patients in the placebo group. "

Related Drugs and Biologics

1.	Dopamine D1 Receptors (Dopamine D1 Receptor)
2.	LY3154207
3.	Poloxamer (Poloxamer 407)
4.	Thioredoxins
5.	Neuropeptides
6.	Insulin (Novolin)
7.	Ceftriaxone (Ceftriaxon)
8.	Ambroxol (Mucosolvan)
9.	Silybin (Lagosa)
10.	Atomoxetine Hydrochloride (Strattera)